Press release
Parkinson's Disease Pipeline Analysis, 2025 by DelveInsight | Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech,
Parkinson's disease pipeline
DelveInsight reports that the Parkinson's Disease pipeline includes over 130 key companies actively developing more than 150 therapeutic candidates.
Parkinson's Disease Overview:
Parkinson's disease (PD) is a chronic, progressive neurological disorder that primarily affects movement. It arises from the gradual loss of dopamine-producing neurons in the substantia nigra, a brain region critical for motor control. Although PD most commonly develops in individuals over 60, it can occasionally occur earlier. It is the second most common neurodegenerative disease after Alzheimer's, and its progression varies widely among patients, making prediction and management challenging.
The primary motor symptoms of PD include tremors, slowed movement (bradykinesia), muscle stiffness (rigidity), and postural instability. Tremors usually begin in a single limb, often the hand or fingers, and are most noticeable at rest. Bradykinesia can significantly interfere with daily activities by slowing voluntary movements. Muscle rigidity leads to stiffness and limited motion, while postural instability increases the risk of falls. PD also presents with non-motor symptoms, including sleep disturbances, depression, anxiety, cognitive impairment, and autonomic nervous system dysfunction.
Download our report @ https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Parkinson's Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parkinson's Disease Therapeutics Market.
Key Takeaways from the Parkinson's Disease Pipeline Report
DelveInsight's Parkinson's Disease (PD) pipeline report highlights a vibrant landscape, with over 130 companies actively developing more than 150 therapeutic candidates.
Key regulatory updates include:
*
February 2025: The FDA approved Medtronic's BrainSense Adaptive Deep Brain Stimulation (aDBS) system, which adjusts stimulation in real-time based on brain signals, offering more personalized symptom management compared to traditional continuous DBS devices.
*
February 4, 2025: The FDA approved Onapgo (apomorphine hydrochloride), a continuous subcutaneous infusion therapy for PD patients experiencing significant "off" episodes, when standard medications are less effective.
*
October 2024: The FDA approved Vyalev (foscarbidopa and foslevodopa), the first 24-hour subcutaneous continuous levodopa infusion for adults with advanced PD and motor fluctuations, providing consistent dopamine delivery for steady symptom control.
Leading companies developing PD therapies include Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences, Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron, Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune, and others.
Notable PD pipeline therapies in various stages of development include Buntanetap, Tavapadon, Prasinezumab, Risvodetinib, GT 02287, among several additional candidates.
Parkinson's Disease Pipeline Analysis
The Parkinson's Disease pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Parkinson's Disease Market.
*
Categorizes Parkinson's Disease therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Parkinson's Disease drugs under development based on:
*
Stage of development
*
Parkinson's Disease Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Parkinson's Disease Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Parkinson's Disease Licensing agreements
*
Funding and investment activities supporting future Parkinson's Disease market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Parkinson's Disease Emerging Drugs
*
Buntanetap: Annovis Bio
*
Tavapadon: Cerevel Therapeutics
*
Prasinezumab: Roche
*
Risvodetinib: Inhibikase Therapeutics, Inc
*
GT 02287: Gain Therapeutics
*
NNI 362: Neuronascent
Parkinson's Disease Companies
More than 130 leading companies are actively developing therapies for Parkinson's disease, with Annovis Bio advancing a drug candidate to the most advanced stage-Phase III clinical trials.
DelveInsight's report covers around 150+ products under different phases of Parkinson's Disease clinical trials like
*
Parkinson's Disease Late stage Therapies (Phase III)
*
Parkinson's Disease Mid-stage Therapies (Phase II)
*
Parkinson's Disease Early-stage Therapies (Phase I)
*
Parkinson's Disease Pre-clinical and Parkinson's Disease Discovery stage Therapies
*
Parkinson's Disease Discontinued & Inactive Therapies
Parkinson's Disease pipeline report provides the Parkinson's Disease therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Parkinson's Disease Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Parkinson's Disease Therapies and Key Parkinson's Disease Companies: Parkinson's Disease Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Parkinson's Disease Pipeline Therapeutic Assessment
- Parkinson's Disease Assessment by Product Type
- Parkinson's Disease By Stage
- Parkinson's Disease Assessment by Route of Administration
- Parkinson's Disease Assessment by Molecule Type
Download Parkinson's Disease Sample report to know in detail about the Parkinson's Disease treatment market @ Parkinson's Disease Therapeutic Assessment [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Parkinson's Disease Current Treatment Patterns
4. Parkinson's Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Parkinson's Disease Late-Stage Products (Phase-III)
7. Parkinson's Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Parkinson's Disease Discontinued Products
13. Parkinson's Disease Product Profiles
14. Parkinson's Disease Key Companies
15. Parkinson's Disease Key Products
16. Dormant and Discontinued Products
17. Parkinson's Disease Unmet Needs
18. Parkinson's Disease Future Perspectives
19. Parkinson's Disease Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Parkinson's Disease Pipeline Reports Offerings [https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=parkinsons-disease-pipeline-analysis-2025-by-delveinsight-annovis-bio-cerevel-therapeutics-roche-inhibikase-therapeutics-inc-gain-therapeutics-neuronascent-anew-medical-longevity-biotech]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Pipeline Analysis, 2025 by DelveInsight | Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, here
News-ID: 4165690 • Views: …
More Releases from ABNewswire
Phenix City Medical Practice Announces Expanded Healthcare Services, Addressing …
Preferred Medical Group, Phenix City, announces the expansion of its healthcare services and improved patient access, addressing community demand for comprehensive medical care with integrated pediatric, adult, and therapeutic services under one roof.
Preferred Medical Group, Phenix City [https://preferredmedgroup.com/], has announced significant enhancements to its healthcare services, responding to increased community demand for accessible and comprehensive medical care. The medical practice, located at 3700 South Railroad Street, has introduced streamlined patient…
Auburn Medical Practice Expands Integrated Care Model as Primary Care Doctor Add …
Preferred Medical Group - Auburn expands ADHD services and integrated care model, offering comprehensive family medicine, behavioral health, and specialized attention disorder treatment in one convenient East Alabama location.
Preferred Medical Group - Auburn [https://preferredmedgroup.com/] has announced significant enhancements to its integrated healthcare services, responding to increased demand for ADHD treatment and comprehensive family medical care in East Alabama. The Auburn location, situated at 318 Samford Village Court, Suite 100, now…
Local ADHD Doctor Program Launches at Preferred Medical Group - Opelika for East …
Preferred Medical Group - Opelika launches an integrated ADHD treatment program that combines pediatric care, psychiatry, and therapy services to address regional healthcare needs for East Alabama families.
Opelika healthcare providers have taken a significant step toward addressing the growing need for specialized attention deficit hyperactivity disorder services in East Alabama. Preferred Medical Group - Opelika [https://preferredmedgroup.com/] has announced the expansion of comprehensive ADHD treatment programs, integrating pediatric care with behavioral…
Prominent Criminal Lawyer in Galveston Firm Celebrates 25+ Years of Texas Gulf C …
Tad Nelson & Associates celebrates over 25 years of criminal defense excellence across the Texas Gulf Coast, combining local roots, community involvement, and personalized legal services that span multiple counties.
A prominent Texas law firm has reached a significant milestone, celebrating over 25 years of providing criminal defense and family law services across the Greater Houston area and Galveston County. The achievement underscores the firm's steadfast commitment to serving Texas communities…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
